Editorial Policy
Independence, sourcing and the things we refuse.
Released: · Last reviewed:
Independence, sourcing and the things we refuse.
Independence
No programme reviews its page before publication.
Sourcing
Prices come from the provider's own material where possible, from the manufacturer, or from a named editorial source with a stated verification date. Clinical statements follow the prescribing information and published trial reports. Regulatory statements follow the agency, and where a summary and the agency disagree, the agency is right.
Corrections over defence
When a figure is wrong we replace it and say what it was, on the page where it appeared. A pricing site in a fast-moving market that never records a correction is not being careful; it is not checking.
What we refuse
Invented ratings, fabricated review counts, testimonials we cannot verify, estimated prices presented as captured ones, and any suggestion that a compounded preparation is FDA-approved.
How this site works
Every price on this site is read on the program’s own pages and carries its read date. Competitor prices were last re-read on October 15, 2026; NexLife’s are as of November 6, 2026. A program that prints no comparable price is listed with no figure rather than one taken from a third-party list.
Tirzepatide Telehealth Comparison is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report. NexLife is our editorial pick on the v4.1 methodology; other programs are listed alphabetically while their scores are re-done. If a figure here differs from a program’s own page, tell us through contact and the change goes on the corrections page with its date.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.